{"test_cases_lookup_map": {"{\"actual_output\": \"# Clinical Trial Information\\n\\n## Trial ID\\nThe Trial ID for this clinical trial is **Sym004-09** (p. 93, \\u00b61).\\n\\n## EudraCT Number\\nThe EudraCT number is not explicitly mentioned in the provided context.\\n\\n---\\n\\n### Summary\\n- **Trial ID**: Sym004-09\\n- **EudraCT Number**: Not available in the provided context.\", \"context\": null, \"expected_output\": \"Trial ID: Sym004-09; EudraCT number: 2015-003047-19\", \"hyperparameters\": null, \"input\": \"What is the Trial ID and EudraCT number for this clinical trial?\", \"retrieval_context\": [\"Symphogen Clinical Trial Protocol Trial ID: Sym004-09\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Accuracy Metric (dspy llm as judge)", "threshold": 1.0, "success": true, "score": 1.0, "reason": "The text answer correctly identifies the Trial ID as \"Sym004-09,\" which matches the reference answer. However, it does not provide the EudraCT number, stating that it is not mentioned in the provided context. Since the EudraCT number is a crucial part of the reference answer, the text is only partially correct regarding the completeness of the answer. Therefore, the score is 1 for being partially correct.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Completeness Metric (dspy llm as judge)", "threshold": 0.1, "success": true, "score": 0.5, "reason": "The first part, \"Trial ID: Distinct identifier for the clinical trial,\" is covered as the target states the Trial ID is \"Sym004-09.\" The second part, \"EudraCT number: Registration number in the European Clinical Trials Database,\" is not covered as the target text clarifies that this information is not available, which is a correct indication rather than a hallucination. Thus, one part is accurately covered without any hallucinations detected.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 0.1, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 1.0, "success": true, "score": 1.0, "reason": "The score is 1.00 because there are no contradictions present, indicating that the actual output aligns perfectly with the retrieval context.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"The document is a clinical trial protocol.\",\n    \"The trial ID is Sym004-09.\",\n    \"The name of the trial is Symphogen.\"\n] \n \nClaims:\n[\n    \"The Trial ID for this clinical trial is Sym004-09.\",\n    \"The EudraCT number is not explicitly mentioned in the provided context.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": \"The EudraCT number is not mentioned in the context, making it uncertain whether it exists or not, hence the claim cannot be confirmed as true or false.\"\n    }\n]"}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Answer Relevancy", "threshold": 0.8, "success": true, "score": 1.0, "reason": "The score is 1.00 because the response directly addresses the question about the Trial ID and EudraCT number without any irrelevant statements.", "strictMode": false, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"The Trial ID for this clinical trial is Sym004-09.\",\n    \"The EudraCT number is not explicitly mentioned in the provided context.\",\n    \"Trial ID: Sym004-09\",\n    \"EudraCT Number: Not available in the provided context.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The statement indicates that the EudraCT number is not mentioned, which does not provide a definitive answer.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The statement indicates that the EudraCT number is not available, which does not provide a definitive answer.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.8, "evaluation_model": "gpt-4o-mini", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Citation Quality (F1)", "threshold": 0.5, "success": false, "score": 0.0, "reason": "F1 Score: 0.00 (Precision: 0.00, Recall: 0.00). Expected {'1'}, but retrieved {'93'}.", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Latency", "threshold": 0.5, "success": true, "score": 1.0, "reason": "Latency: 5918.45ms (Threshold: 10000ms)", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"## Required ECOG Performance Status for Patient Inclusion\\n\\nTo be eligible for inclusion in the trial, patients must have an **Eastern Cooperative Oncology Group (ECOG) performance status (PS)** of:\\n\\n1. **0** (Fully active, able to carry on all pre-disease activities without restriction)\\n2. **1** (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light nature)\\n\\nThis criterion is essential for ensuring that participants are fit enough to undergo the trial procedures and treatments (p. 38, \\u00b61).\", \"context\": null, \"expected_output\": \"ECOG performance status of 0 or 1\", \"hyperparameters\": null, \"input\": \"What ECOG performance status is required for patient inclusion?\", \"retrieval_context\": [\"Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Accuracy Metric (dspy llm as judge)", "threshold": 1.0, "success": true, "score": 2.0, "reason": "The text accurately describes the required ECOG performance status for patient inclusion, stating that a performance status of 0 or 1 is necessary. It provides detailed definitions for both statuses, which reflects a comprehensive understanding and presentation of the reference answer. Thus, it fully corresponds to the reference answer without any inaccuracies.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Completeness Metric (dspy llm as judge)", "threshold": 0.1, "success": true, "score": 2.0, "reason": "Both parts of the reference text are covered in the target text. The definitions of the ECOG performance status scores (0 and 1) are correctly described, and the phrasing aligns well with the reference, affirming the accuracy of the information without any hallucinations.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 0.1, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 1.0, "success": true, "score": 1.0, "reason": "The score is 1.00 because there are no contradictions present, indicating that the actual output aligns perfectly with the retrieval context.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"ECOG performance status is a measure used in oncology.\",\n    \"ECOG performance status of 0 indicates that the patient is fully active and able to carry on all pre-disease activities.\",\n    \"ECOG performance status of 1 indicates that the patient is restricted in physically strenuous activity but is ambulatory and able to carry out work of a light nature.\"\n] \n \nClaims:\n[\n    \"Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 to be eligible for inclusion in the trial.\",\n    \"An ECOG performance status of 0 means the patient is fully active and able to carry on all pre-disease activities without restriction.\",\n    \"An ECOG performance status of 1 means the patient is restricted in physically strenuous activity but is ambulatory and able to carry out work of a light nature.\",\n    \"The criterion of ECOG performance status is essential for ensuring that participants are fit enough to undergo the trial procedures and treatments.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": \"The claim is correct as it aligns with the context that ECOG performance status of 0 or 1 is used for eligibility.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": \"The claim accurately reflects the definition of ECOG performance status of 0.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": \"The claim accurately reflects the definition of ECOG performance status of 1.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": \"The claim is supported by the context that ECOG performance status is a measure of fitness for trial procedures.\"\n    }\n]"}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Answer Relevancy", "threshold": 0.8, "success": true, "score": 1.0, "reason": "The score is 1.00 because the response directly addressed the question about ECOG performance status without any irrelevant statements.", "strictMode": false, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 to be eligible for inclusion in the trial.\",\n    \"ECOG performance status 0 means fully active, able to carry on all pre-disease activities without restriction.\",\n    \"ECOG performance status 1 means restricted in physically strenuous activity but ambulatory and able to carry out work of a light nature.\",\n    \"This criterion is essential for ensuring that participants are fit enough to undergo the trial procedures and treatments.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.8, "evaluation_model": "gpt-4o-mini", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Citation Quality (F1)", "threshold": 0.5, "success": true, "score": 1.0, "reason": "F1 Score: 1.00 (Precision: 1.00, Recall: 1.00). Expected {'38'}, but retrieved {'38'}.", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Latency", "threshold": 0.5, "success": true, "score": 1.0, "reason": "Latency: 5541.38ms (Threshold: 10000ms)", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"# Sponsor of the Clinical Trial\\n\\nThe sponsor of this clinical trial is **Leading Biopharm Limited**. This information is confirmed in the protocol documentation, which outlines the responsibilities and ethical considerations for conducting the trial.\\n\\n## Key Details\\n- **Protocol Title**: Ulcerative Colitis\\n- **Protocol Number**: CTJ301UC201\\n- **Date**: 16 May 2017\\n\\nThe study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and all applicable laws and regulations (p. 2, \\u00b61).\", \"context\": null, \"expected_output\": \"Symphogen A/S\", \"hyperparameters\": null, \"input\": \"Who is the sponsor of this clinical trial?\", \"retrieval_context\": [\"Leading Biopharm Limited\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Accuracy Metric (dspy llm as judge)", "threshold": 1.0, "success": false, "score": 0.0, "reason": "The text states that the sponsor of the clinical trial is \"Leading Biopharm Limited,\" which does not match the reference answer, \"Symphogen A/S.\" Therefore, the text is incorrect regarding the identity of the sponsor. There is no indication that the sponsor is the correct entity, leading to a score of 0 for incorrectness.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Completeness Metric (dspy llm as judge)", "threshold": 0.1, "success": true, "score": 1.0, "reason": "No reference parts to cover, so no analysis of coverage can be performed.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 0.1, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 1.0, "success": true, "score": 1.0, "reason": "The score is 1.00 because there are no contradictions present, indicating that the actual output aligns perfectly with the retrieval context.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"Leading Biopharm Limited is a company.\"\n] \n \nClaims:\n[\n    \"The sponsor of the clinical trial is Leading Biopharm Limited.\",\n    \"The information about the sponsor is confirmed in the protocol documentation.\",\n    \"The protocol title of the clinical trial is Ulcerative Colitis.\",\n    \"The protocol number of the clinical trial is CTJ301UC201.\",\n    \"The date of the protocol is 16 May 2017.\",\n    \"The study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki.\",\n    \"The study will comply with all applicable laws and regulations.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide information about the sponsor of the clinical trial.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not confirm the information about the sponsor in the protocol documentation.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide the protocol title of the clinical trial.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide the protocol number of the clinical trial.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide the date of the protocol.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Answer Relevancy", "threshold": 0.8, "success": false, "score": 0.14285714285714285, "reason": "The score is 0.14 because the output repeatedly failed to address the question about the sponsor of the clinical trial, providing irrelevant information instead. This lack of relevant content significantly lowered the score, as the core inquiry was not answered.", "strictMode": false, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"The sponsor of the clinical trial is Leading Biopharm Limited.\",\n    \"The protocol documentation outlines the responsibilities and ethical considerations for conducting the trial.\",\n    \"The protocol title is Ulcerative Colitis.\",\n    \"The protocol number is CTJ301UC201.\",\n    \"The date of the protocol is 16 May 2017.\",\n    \"The study will be conducted in accordance with the ethical principles from the Declaration of Helsinki.\",\n    \"The study will comply with all applicable laws and regulations.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the sponsor of the clinical trial.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the sponsor of the clinical trial.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the sponsor of the clinical trial.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the sponsor of the clinical trial.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the sponsor of the clinical trial.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the sponsor of the clinical trial.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.8, "evaluation_model": "gpt-4o-mini", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Citation Quality (F1)", "threshold": 0.5, "success": false, "score": 0.0, "reason": "F1 Score: 0.00 (Precision: 0.00, Recall: 0.00). Expected {'1'}, but retrieved {'2'}.", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Latency", "threshold": 0.5, "success": true, "score": 1.0, "reason": "Latency: 5008.72ms (Threshold: 10000ms)", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"# Total Planned Number of Patients for the Trial\\n\\nThe total planned number of patients for this trial is **90**. This number accounts for a competitive enrollment of patients with active Ulcerative Colitis (UC) across approximately 25-30 investigational sites globally. The patients will be randomized equally into three arms, which include two dose levels of the investigational product (TJ301) and a placebo group (p. 29, \\u00b61). \\n\\n## Key Points\\n1. **Sample Size**: \\n   - The trial aims to enroll **90 patients** to ensure adequate power for detecting treatment effects.\\n   - This includes a consideration of a dropout rate of approximately **20%**.\\n\\n2. **Randomization**: \\n   - Patients will be randomized into three groups: \\n     - Placebo \\n     - TJ301 300 mg \\n     - TJ301 600 mg \\n\\n3. **Trial Duration**: \\n   - The expected total duration of the trial is approximately **2.5 years**, with the first patient visit planned for the **Third Quarter of 2017** and the last patient visit for the **First Quarter of 2020** (p. 29, \\u00b61).\", \"context\": null, \"expected_output\": \"50 patients total (up to 18 in dose-escalation, 32-41 in dose-expansion)\", \"hyperparameters\": null, \"input\": \"What is the total planned number of patients for this trial?\", \"retrieval_context\": [\"In total, 90 patients with active UC at approximately 25-30 investigational sites globally will be enrolled competitively and randomised equally into three arms with TJ301 (two dose levels) or placebo.\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Accuracy Metric (dspy llm as judge)", "threshold": 1.0, "success": false, "score": 0.0, "reason": "The text answer states a total planned number of 90 patients for the trial, which contradicts the reference answer that specifies 50 patients total (with specifics regarding dose-escalation and dose-expansion). Since the main question is about the total number of patients, the text is incorrect in its claim. Therefore, it is a 0 for being wrong/incorrect.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Completeness Metric (dspy llm as judge)", "threshold": 0.1, "success": false, "score": 0.0, "reason": "The target text inaccurately states that the total planned number of patients for the trial is 90, while the reference indicates there are 50 patients in total for the trial. Additionally, the coverage analysis reveals two distinct reference parts: one about the total patient count and another regarding patient allocation, neither of which is correctly represented in the target text. Due to this hallucination and the lack of accurate coverage, the count of covered parts is zero.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 0.1, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 1.0, "success": false, "score": 0.0, "reason": "The score is 0.00 because the actual output incorrectly identifies three groups, including specific doses for TJ301, while the retrieval context only mentions two dose levels and a placebo without detailing the doses.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"90 patients with active UC will be enrolled.\",\n    \"The enrollment will take place at approximately 25-30 investigational sites globally.\",\n    \"Patients will be randomized equally into three arms.\",\n    \"The three arms will include TJ301 at two dose levels and a placebo.\"\n] \n \nClaims:\n[\n    \"The total planned number of patients for the trial is 90.\",\n    \"The trial will enroll patients with active Ulcerative Colitis (UC) across approximately 25-30 investigational sites globally.\",\n    \"Patients will be randomized equally into three arms: a placebo group, a TJ301 300 mg group, and a TJ301 600 mg group.\",\n    \"The trial aims to enroll 90 patients to ensure adequate power for detecting treatment effects.\",\n    \"The trial considers a dropout rate of approximately 20%.\",\n    \"The expected total duration of the trial is approximately 2.5 years.\",\n    \"The first patient visit is planned for the Third Quarter of 2017.\",\n    \"The last patient visit is planned for the First Quarter of 2020.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": \"The claim specifies the number of investigational sites as 25-30, which aligns with the context provided.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The claim specifies the arms as a placebo group, a TJ301 300 mg group, and a TJ301 600 mg group, while the context only mentions two dose levels of TJ301 and a placebo without specifying the exact doses.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide information about the trial's power or the rationale for the planned number of patients.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not mention any considerations regarding dropout rates.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide information about the expected duration of the trial.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not specify the timing of patient visits.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not specify the timing of the last patient visit.\"\n    }\n]"}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Answer Relevancy", "threshold": 0.8, "success": false, "score": 0.25, "reason": "The score is 0.25 because the output included several irrelevant statements that provided details about the enrollment process, randomization, dropout rates, trial duration, and patient visit timings, none of which directly answered the question about the total planned number of patients.", "strictMode": false, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"The total planned number of patients for the trial is 90.\",\n    \"The trial accounts for a competitive enrollment of patients with active Ulcerative Colitis (UC) across approximately 25-30 investigational sites globally.\",\n    \"Patients will be randomized equally into three arms: placebo, TJ301 300 mg, and TJ301 600 mg.\",\n    \"The trial aims to enroll 90 patients to ensure adequate power for detecting treatment effects.\",\n    \"There is a consideration of a dropout rate of approximately 20%.\",\n    \"The expected total duration of the trial is approximately 2.5 years.\",\n    \"The first patient visit is planned for the Third Quarter of 2017.\",\n    \"The last patient visit is planned for the First Quarter of 2020.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement provides information about the enrollment process but does not directly answer the question about the total planned number of patients.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement describes the randomization process but does not provide the total planned number of patients.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement discusses dropout rates, which is not directly relevant to the total planned number of patients.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement provides information about the trial duration but does not address the total planned number of patients.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement mentions the timing of the first patient visit but does not relate to the total planned number of patients.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement refers to the timing of the last patient visit and does not provide information about the total planned number of patients.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.8, "evaluation_model": "gpt-4o-mini", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Citation Quality (F1)", "threshold": 0.5, "success": false, "score": 0.0, "reason": "F1 Score: 0.00 (Precision: 0.00, Recall: 0.00). Expected {'15', '16', '37'}, but retrieved {'29'}.", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Latency", "threshold": 0.5, "success": true, "score": 1.0, "reason": "Latency: 8452.75ms (Threshold: 10000ms)", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"# Dose Level 1 for Sym004 in the Dose-Escalation Phase\\n\\nIn the dose-escalation phase of the trial, **Dose Level 1** for Sym004 is defined as:\\n\\n- **Sym004 12 mg/kg + FOLFIRI**\\n\\nThis starting dose is part of a structured approach to evaluate the safety and tolerability of Sym004 in combination with FOLFIRI, administered every second week (Day 1 and Day 15 of each 28-day cycle, \\u00b1 2 days) (p. 16, \\u00b61). \\n\\n## Summary of Dose Levels\\n1. **Dose Level 1**: Sym004 12 mg/kg + FOLFIRI\\n2. **Dose Level 2**: Sym004 15 mg/kg + FOLFIRI\\n3. **Dose Level 3**: Sym004 18 mg/kg + FOLFIRI\\n4. **Dose Level -1**: Sym004 9 mg/kg + FOLFIRI (if Dose Level 1 is not tolerated)\\n5. **Dose Level -2**: Sym004 9 mg/kg (loading dose) + FOLFIRI followed by 6 mg/kg + FOLFIRI\\n6. **Dose Level -3**: Sym004 6 mg/kg + FOLFIRI\\n\\nThe trial will proceed to lower doses if the toxicity profile indicates that the higher doses are not tolerated (p. 47, \\u00b61).\", \"context\": null, \"expected_output\": \"Dose Level 1: Sym004 12 mg/kg + FOLFIRI\", \"hyperparameters\": null, \"input\": \"What is Dose Level 1 (the starting dose) for Sym004 in the dose-escalation phase?\", \"retrieval_context\": [\"Dose Level 1: Sym004 12 mg/kg + FOLFIRI\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Accuracy Metric (dspy llm as judge)", "threshold": 1.0, "success": true, "score": 2.0, "reason": "The text provides the correct information about Dose Level 1 for Sym004, stating it is \"Sym004 12 mg/kg + FOLFIRI,\" which matches the reference answer. Additionally, it offers further relevant context about the dose-escalation phase while remaining focused on the question at hand. Therefore, it is fully correct.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Completeness Metric (dspy llm as judge)", "threshold": 0.1, "success": true, "score": 1.0, "reason": "The reference part states that Dose Level 1 consists of \"Sym004 12 mg/kg + FOLFIRI,\" which is directly repeated in the target text. The target text also provides additional contextual information about the trial phase and administration schedule, all of which aligns with the reference without any inconsistencies. Therefore, there are no hallucinations detected, and the reference part is fully covered.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 0.1, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 1.0, "success": false, "score": 0.0, "reason": "The score is 0.00 because the actual output includes information about multiple dose levels that are not mentioned in the retrieval context, which only specifies Dose Level 1 (12 mg/kg). This discrepancy indicates a complete lack of faithfulness to the provided context.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"Dose Level 1 involves Sym004 at a dosage of 12 mg/kg.\",\n    \"FOLFIRI is included in Dose Level 1.\"\n] \n \nClaims:\n[\n    \"Dose Level 1 for Sym004 is defined as Sym004 12 mg/kg + FOLFIRI.\",\n    \"Dose Level 1 is part of a structured approach to evaluate the safety and tolerability of Sym004 in combination with FOLFIRI.\",\n    \"Sym004 is administered every second week on Day 1 and Day 15 of each 28-day cycle, with a tolerance of \u00b1 2 days.\",\n    \"The trial includes multiple dose levels: Dose Level 1 (12 mg/kg), Dose Level 2 (15 mg/kg), Dose Level 3 (18 mg/kg), Dose Level -1 (9 mg/kg if Dose Level 1 is not tolerated), Dose Level -2 (9 mg/kg loading dose followed by 6 mg/kg), and Dose Level -3 (6 mg/kg).\",\n    \"The trial will proceed to lower doses if the toxicity profile indicates that the higher doses are not tolerated.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not specify the administration schedule for Sym004.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The context only mentions Dose Level 1 (12 mg/kg) and does not provide information about Dose Levels 2, 3, -1, -2, or -3.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide information about the trial's progression based on toxicity profiles.\"\n    }\n]"}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Answer Relevancy", "threshold": 0.8, "success": false, "score": 0.6666666666666666, "reason": "The score is 0.67 because the output included irrelevant statements about Dose Levels 2, 3, and -3, which do not address the specific question about Dose Level 1 for Sym004. These extraneous details detracted from the focus on the requested information, preventing a higher score.", "strictMode": false, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Dose Level 1 for Sym004 is defined as Sym004 12 mg/kg + FOLFIRI.\",\n    \"Dose Level 1 is part of a structured approach to evaluate safety and tolerability.\",\n    \"Sym004 is administered every second week on Day 1 and Day 15 of each 28-day cycle.\",\n    \"Dose Level 2 is Sym004 15 mg/kg + FOLFIRI.\",\n    \"Dose Level 3 is Sym004 18 mg/kg + FOLFIRI.\",\n    \"Dose Level -1 is Sym004 9 mg/kg + FOLFIRI if Dose Level 1 is not tolerated.\",\n    \"Dose Level -2 is Sym004 9 mg/kg (loading dose) + FOLFIRI followed by 6 mg/kg + FOLFIRI.\",\n    \"Dose Level -3 is Sym004 6 mg/kg + FOLFIRI.\",\n    \"The trial will proceed to lower doses if the toxicity profile indicates that higher doses are not tolerated.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"While this statement provides information about the administration schedule, it does not directly address the starting dose.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement discusses Dose Level 2, which is not relevant to the question about Dose Level 1.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement discusses Dose Level 3, which is not relevant to the question about Dose Level 1.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement mentions a lower dose if Dose Level 1 is not tolerated, but does not provide information about Dose Level 1 itself.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement discusses a loading dose and subsequent doses, which may relate to Dose Level 1 but does not directly answer the question.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement discusses Dose Level -3, which is not relevant to the question about Dose Level 1.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement discusses the trial's approach to dose escalation based on toxicity, which is related but does not directly answer the question about Dose Level 1.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.8, "evaluation_model": "gpt-4o-mini", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Citation Quality (F1)", "threshold": 0.5, "success": false, "score": 0.0, "reason": "F1 Score: 0.00 (Precision: 0.00, Recall: 0.00). Expected {'45'}, but retrieved {'16'}.", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Latency", "threshold": 0.5, "success": true, "score": 0.9976263600718759, "reason": "Latency: 10023.79ms (Threshold: 10000ms)", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"# Administration of Sym004\\n\\nSym004 is administered as part of a clinical trial in combination with FOLFIRI. The treatment schedule is as follows:\\n\\n1. **Frequency of Administration**:\\n   - Sym004 is administered **every second week**.\\n   - Specifically, it is given on **Day 1 and Day 15** of each **28-day cycle** (\\u00b1 2 days).\\n\\n2. **Order of Administration**:\\n   - Sym004 is infused **first**, followed by FOLFIRI.\\n   - There is a **minimum interval of 1 hour** between the end of Sym004 infusion and the start of FOLFIRI infusion.\\n\\n3. **Dosing**:\\n   - The dose of Sym004 varies based on the cohort to which the patient is allocated and is documented on an allocation form.\\n   - There will be **no intra-patient dose escalation** (p. 33, \\u00b61).\\n\\n4. **Infusion Method**:\\n   - Sym004 is administered via **IV infusion** through a peripheral line or indwelling catheter, using an infusion pump and an inline filter (p. 45, \\u00b61).\\n\\n5. **Monitoring**:\\n   - Patients are monitored closely during and after the infusion to manage any potential infusion-related reactions (p. 47, \\u00b61).\\n\\nThis structured approach ensures that the administration of Sym004 is consistent and safe for all participants in the trial.\", \"context\": null, \"expected_output\": \"Sym004 is administered every second week (Day 1 and Day 15 of each 28-day cycle, \\u00b12 days) by IV infusion.\", \"hyperparameters\": null, \"input\": \"How often is Sym004 administered and on which days of the cycle?\", \"retrieval_context\": [\"All patients will be given iv infusions of Sym004, administered every second week (Day 1 and Day 15 of each 28 day cycle \\u00b12 days) through a peripheral line or indwelling catheter, and with the use of an infusion pump and an inline filter.\", \"Both therapies will be administered every second week by iv infusion (Day 1 and Day 15 of each 28 day cycle, \\u00b1 2 days). Sym004 will be administered first, followed by FOLFIRI, with a minimum interval of 1 hour between Sym004 End of Infusion (EOI) and FOLFIRI SOI.\", \"Each patient enrolled will receive doses of Sym004 at the allocated dose, unless dose-reduction is necessary as specified in Section 7.1.5. There will be no intra-patient dose-escalation.\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Accuracy Metric (dspy llm as judge)", "threshold": 1.0, "success": true, "score": 2.0, "reason": "The text answer accurately describes the frequency and timing of Sym004 administration as specified in the reference answer. It mentions that Sym004 is given every second week on Day 1 and Day 15 of a 28-day cycle, which aligns perfectly with the reference answer. Although the additional details about administration order, dosing, infusion method, and monitoring are not part of the reference answer, they do not detract from the accuracy of the core information regarding the administration schedule. Therefore, the text is fully correct in the context of the question asked.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Completeness Metric (dspy llm as judge)", "threshold": 0.1, "success": true, "score": 1.0, "reason": "- **Administration schedule**: \"Sym004 is administered every second week\" matches the reference part \"Administration schedule: every second week\".\n- **Specific days of administration**: \"Specifically, it is given on Day 1 and Day 15\" aligns with the reference part \"Specific days of administration: Day 1 and Day 15\".\n- **Method of delivery**: \"administered via IV infusion\" corresponds directly to the reference part \"Method of delivery: IV infusion\".\nAll parts from the reference are accurately covered with no hallucinations present.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 0.1, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 1.0, "success": false, "score": 0.0, "reason": "The score is 0.00 because the actual output contradicts the retrieval context by stating that the dose of Sym004 is fixed and does not vary based on the cohort, which implies a lack of flexibility that is not supported by the context.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"Both therapies will be administered every second week.\",\n    \"The administration schedule is on Day 1 and Day 15 of each 28 day cycle, with a \u00b12 days variation.\",\n    \"Sym004 will be administered first, followed by FOLFIRI.\",\n    \"There is a minimum interval of 1 hour between the end of Sym004 infusion and the start of FOLFIRI.\",\n    \"All patients will receive iv infusions of Sym004.\",\n    \"Sym004 will be administered through a peripheral line or indwelling catheter.\",\n    \"An infusion pump and an inline filter will be used for the administration of Sym004.\",\n    \"Each patient enrolled will receive doses of Sym004 at the allocated dose.\",\n    \"Dose-reduction of Sym004 is possible as specified in Section 7.1.5.\",\n    \"There will be no intra-patient dose-escalation.\"\n] \n \nClaims:\n[\n    \"Sym004 is administered as part of a clinical trial in combination with FOLFIRI.\",\n    \"Sym004 is administered every second week.\",\n    \"Sym004 is given on Day 1 and Day 15 of each 28-day cycle (\u00b1 2 days).\",\n    \"Sym004 is infused first, followed by FOLFIRI.\",\n    \"There is a minimum interval of 1 hour between the end of Sym004 infusion and the start of FOLFIRI infusion.\",\n    \"The dose of Sym004 varies based on the cohort to which the patient is allocated and is documented on an allocation form.\",\n    \"There will be no intra-patient dose escalation.\",\n    \"Sym004 is administered via IV infusion through a peripheral line or indwelling catheter, using an infusion pump and an inline filter.\",\n    \"Patients are monitored closely during and after the infusion to manage any potential infusion-related reactions.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The dose of Sym004 is fixed at the allocated dose for each patient, and dose-reduction is possible, but it does not vary based on the cohort.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide information about patient monitoring during and after the infusion.\"\n    }\n]"}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Answer Relevancy", "threshold": 0.8, "success": false, "score": 0.2, "reason": "The score is 0.20 because the output repeatedly failed to address the specific question about the frequency and days of administration for Sym004, leading to multiple irrelevant statements. This lack of relevant information significantly lowered the score.", "strictMode": false, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Sym004 is administered as part of a clinical trial in combination with FOLFIRI.\",\n    \"Sym004 is administered every second week.\",\n    \"Sym004 is given on Day 1 and Day 15 of each 28-day cycle (\u00b1 2 days).\",\n    \"Sym004 is infused first, followed by FOLFIRI.\",\n    \"There is a minimum interval of 1 hour between the end of Sym004 infusion and the start of FOLFIRI infusion.\",\n    \"The dose of Sym004 varies based on the cohort to which the patient is allocated.\",\n    \"There will be no intra-patient dose escalation.\",\n    \"Sym004 is administered via IV infusion through a peripheral line or indwelling catheter.\",\n    \"An infusion pump and an inline filter are used for the administration of Sym004.\",\n    \"Patients are monitored closely during and after the infusion to manage any potential infusion-related reactions.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the frequency or specific days of administration.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": \"This statement directly addresses the frequency of administration.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": \"This statement specifies the days of administration within the cycle.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not address the frequency or specific days of administration.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the frequency or specific days of administration.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not address the frequency or specific days of administration.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the frequency or specific days of administration.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not address the frequency or specific days of administration.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not provide information about the frequency or specific days of administration.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement does not address the frequency or specific days of administration.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.8, "evaluation_model": "gpt-4o-mini", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Citation Quality (F1)", "threshold": 0.5, "success": false, "score": 0.4, "reason": "F1 Score: 0.40 (Precision: 0.33, Recall: 0.50). Expected {'32', '45'}, but retrieved {'45', '47', '33'}.", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Latency", "threshold": 0.5, "success": true, "score": 0.7124744113490874, "reason": "Latency: 14035.59ms (Threshold: 10000ms)", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"# Overview of Sym004\\n\\n**Sym004** is an investigational medicinal product (IMP) that is a **1:1 mixture** of two recombinant, human-mouse chimeric immunoglobulin G1 (IgG1) antibodies. These antibodies specifically bind to two **non-overlapping epitopes** of the **Epidermal Growth Factor Receptor (EGFR)**.\\n\\n## Monoclonal Antibodies in Sym004\\n\\nThe two monoclonal antibodies contained in Sym004 are:\\n1. **mAb992** (also known as **futuximab**)\\n2. **mAb1024** (also known as **modotuximab**)\\n\\nThese antibodies work together to induce a distinct mechanism of action that leads to the internalization and degradation of the EGFR, ultimately inhibiting cancer cell growth (p. 20, \\u00b61). \\n\\n## Mechanism of Action\\n\\n- **Binding**: Sym004 binds to non-overlapping epitopes on domain III of the EGFR.\\n- **Internalization**: The binding induces efficient internalization of EGFR on cancer cells.\\n- **Degradation**: This process leads to down-regulation of EGFR and subsequent inhibition of cancer cell growth (p. 20, \\u00b61).\\n\\n## Clinical Relevance\\n\\nSym004 has shown promising results in clinical trials, particularly in patients with metastatic colorectal cancer (mCRC) who are resistant to anti-EGFR antibody therapy (p. 22, \\u00b61). \\n\\n---\", \"context\": null, \"expected_output\": \"Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs): mAb992 (futuximab) and mAb1024 (modotuximab), which bind specifically to 2 non-overlapping epitopes of the EGFR.\", \"hyperparameters\": null, \"input\": \"What is Sym004 and what are the two monoclonal antibodies it contains?\", \"retrieval_context\": [\"Sym004 binds to non-overlapping epitopes on domain III of the EGFR. The binding of Sym004 induces a distinct mechanism of action that is dependent on the presence of both antibodies.\", \"Sym004 is a 1:1 mixture of 2 recombinant, human-mouse chimeric, immunoglobulin G1 (IgG1) antibodies (referred to as mAb992 [futuximab] and mAb1024 [modotuximab]), which bind specifically to 2 non-overlapping epitopes of the EGFR.\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Accuracy Metric (dspy llm as judge)", "threshold": 1.0, "success": true, "score": 2.0, "reason": "The text provided accurately describes Sym004 as a 1:1 mixture of two monoclonal antibodies, mAb992 (futuximab) and mAb1024 (modotuximab), and correctly mentions that these antibodies bind to non-overlapping epitopes of the EGFR. Additionally, it includes relevant context about the mechanism of action and clinical relevance, which enhances understanding without deviating from the core question. Therefore, the answer is fully correct, matching the reference answer in both content and specificity.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Completeness Metric (dspy llm as judge)", "threshold": 0.1, "success": true, "score": 1.0, "reason": "1. The product designation of Sym004 is clearly stated as a therapeutic product made up of two monoclonal antibodies.\n2. Both monoclonal antibodies are specified correctly as mAb992 (futuximab) and mAb1024 (modotuximab).\n3. The binding specificity to non-overlapping epitopes of the EGFR is accurately reflected in the target text.\n\nAll parts from the reference are covered without any hallucinations detected.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0}, "metric_configuration": {"threshold": 0.1, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 1.0, "success": false, "score": 0.0, "reason": "The score is 0.00 because the actual output incorrectly states that the antibodies in Sym004 lead to internalization and degradation of EGFR, which is not mentioned in the context. Additionally, it claims that this process results in down-regulation of EGFR and inhibition of cancer cell growth, which is also unsupported by the context.", "strictMode": true, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"Sym004 is a 1:1 mixture of 2 recombinant, human-mouse chimeric, immunoglobulin G1 (IgG1) antibodies.\",\n    \"The antibodies in Sym004 are referred to as mAb992 (futuximab) and mAb1024 (modotuximab).\",\n    \"Sym004 binds specifically to 2 non-overlapping epitopes of the EGFR.\",\n    \"Sym004 binds to non-overlapping epitopes on domain III of the EGFR.\",\n    \"The binding of Sym004 induces a distinct mechanism of action.\",\n    \"The mechanism of action of Sym004 is dependent on the presence of both antibodies.\"\n] \n \nClaims:\n[\n    \"Sym004 is an investigational medicinal product (IMP).\",\n    \"Sym004 is a 1:1 mixture of two recombinant, human-mouse chimeric immunoglobulin G1 (IgG1) antibodies.\",\n    \"The antibodies in Sym004 specifically bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).\",\n    \"The two monoclonal antibodies contained in Sym004 are mAb992 (also known as futuximab) and mAb1024 (also known as modotuximab).\",\n    \"The antibodies in Sym004 work together to induce a distinct mechanism of action that leads to the internalization and degradation of the EGFR.\",\n    \"The binding of Sym004 induces efficient internalization of EGFR on cancer cells.\",\n    \"The internalization and degradation of EGFR leads to down-regulation of EGFR and subsequent inhibition of cancer cell growth.\",\n    \"Sym004 has shown promising results in clinical trials.\",\n    \"Sym004 has shown promising results particularly in patients with metastatic colorectal cancer (mCRC) who are resistant to anti-EGFR antibody therapy.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide information about whether Sym004 is classified as an investigational medicinal product (IMP).\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The context does not mention that the antibodies in Sym004 lead to internalization and degradation of the EGFR.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide information about the efficiency of internalization of EGFR on cancer cells.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The context does not mention that internalization and degradation of EGFR leads to down-regulation of EGFR and subsequent inhibition of cancer cell growth.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not provide information about the results of clinical trials for Sym004.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"The context does not specify the results of Sym004 in patients with metastatic colorectal cancer (mCRC) who are resistant to anti-EGFR antibody therapy.\"\n    }\n]"}, "metric_configuration": {"threshold": 1.0, "evaluation_model": "gpt-4o-mini", "strict_mode": true, "include_reason": true}}, {"metric_data": {"name": "Answer Relevancy", "threshold": 0.8, "success": true, "score": 1.0, "reason": "The score is 1.00 because the response directly addresses the question about Sym004 and its monoclonal antibodies without any irrelevant statements.", "strictMode": false, "evaluationModel": "gpt-4o-mini", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Sym004 is an investigational medicinal product (IMP).\",\n    \"Sym004 is a 1:1 mixture of two recombinant, human-mouse chimeric immunoglobulin G1 (IgG1) antibodies.\",\n    \"The antibodies in Sym004 specifically bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).\",\n    \"The two monoclonal antibodies in Sym004 are mAb992 (futuximab) and mAb1024 (modotuximab).\",\n    \"The antibodies work together to induce a distinct mechanism of action.\",\n    \"The mechanism of action leads to the internalization and degradation of the EGFR.\",\n    \"The internalization and degradation of EGFR inhibit cancer cell growth.\",\n    \"Sym004 binds to non-overlapping epitopes on domain III of the EGFR.\",\n    \"The binding of Sym004 induces efficient internalization of EGFR on cancer cells.\",\n    \"The process leads to down-regulation of EGFR.\",\n    \"Sym004 has shown promising results in clinical trials.\",\n    \"Sym004 is particularly effective in patients with metastatic colorectal cancer (mCRC) who are resistant to anti-EGFR antibody therapy.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"While the statement discusses the mechanism of action, it does not directly answer the question about what Sym004 is or the specific monoclonal antibodies it contains.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement describes the mechanism of action but does not provide information about the monoclonal antibodies or what Sym004 is.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement discusses the effect of the mechanism of action but does not directly address the question about Sym004 or its components.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement provides information about the binding characteristics but does not directly answer the question about the monoclonal antibodies.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement discusses the binding and internalization process but does not directly address the question about Sym004 or its components.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement discusses the down-regulation of EGFR but does not provide information about the monoclonal antibodies or what Sym004 is.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement mentions clinical trial results but does not directly address the question about Sym004 or its components.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": \"This statement discusses effectiveness in a specific patient population but does not provide information about the monoclonal antibodies or what Sym004 is.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.8, "evaluation_model": "gpt-4o-mini", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Citation Quality (F1)", "threshold": 0.5, "success": true, "score": 1.0, "reason": "F1 Score: 1.00 (Precision: 1.00, Recall: 1.00). Expected {'20', '19'}, but retrieved {'20', '19'}.", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Latency", "threshold": 0.5, "success": true, "score": 0.8406008354135968, "reason": "Latency: 11896.25ms (Threshold: 10000ms)", "strictMode": false, "evaluationCost": 0}, "metric_configuration": {"threshold": 0.5, "strict_mode": false, "include_reason": true}}]}}}